(2005). DM: An expanding role for mTOR in cancer. Trends Mol Med
(2007). DM: Defining the role of mTOR in cancer. Cancer Cell
(2007). Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res
(2005). E: MTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology
(1998). Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol
(2009). et al: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as secondline treatment of advanced non-small-cell lung cancer.
(2007). et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
(2010). et al: Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
(2010). Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep
(2008). Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett
(2006). Hershko DD: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res
(2010). Huang B: Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci
(2006). IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes.
(2009). Khuri FR: The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Oncologist
(2004). MericBernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res
(2007). Orntoft TF: Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res
(2010). Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer
(2004). PJ: The TOR pathway: A target for cancer therapy. Nature Reviews Cancer
(2005). Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther
(1998). Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability.